All News

Convention1.jpg

EULAR 2023: Featured Industry Presentations

Jack Cush, MD

EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR

Read Article
RheumNow Podcast square

3-4-5 Rule (5.26.2023)

Jack Cush, MD

Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.

Read Article
Rheumatoid,RA,nodules,damage

Prevalence of Psoriatic Arthritis, Spondyloarthritis and Rheumatoid Arthritis in Norway

Jack Cush, MD

Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA).

Read Article
NSAIDs.pills_.caps_.jpg

NSAID Prescribing Decreasing

Jack Cush, MD

Multinational metanalyses of data between 1989 and 2022 shows that NSAID prescriptions have decreased over time, and differs according to geographical locations.

Read Article
RheumNow Podcast square

Allergic Drug-Induced Arthritis (5.19.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.

Read Article
psA.fil_.Hands_.jpg

Brepocitinib in Active Psoriatic Arthritis

Jack Cush, MD

Brepocitinib is a novel tyrosine kinase 2/Janus kinase 1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks.

Read Article
PSA068.jpg

Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis

Jack Cush, MD

Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients.

Read Article
Comorbidities and metabolic burden in PsA: -Occur EARLY -Early PsA pts > multiple comorbidities & > CV morbidity vs. age-matched early RA pts Independent of BMI & obesity Time to address these as part of dis pathogenesis in PsA https://t.co/qOiGHn2eZT OP0066 #EULAR23 @Rheumnow https://t.co/lK7MbeMybO

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for: -KOL perspective videos -Clinical Trial Highlights -Daily Faculty Recaps -Live Streaming and more! https://t.co/9uKnDTynfk
Dr. John Cush RheumNow ( View Tweet)
Brepocitinib in Active PsA Brepocitinib is a novel tyrosine kinase 2/JAK1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks. https://t.co/qzOVsLMkYe https://t.co/ouLyB131r8

Links:

Dr. John Cush RheumNow ( View Tweet)
Swedish registry review of #MTX initiation in early #PsA vs #RA (n 3642each). 2 years after MTX start, 71% of PsA vs 76% of patients with RA remained on MTX & the majority (66%/60%) had not started another DMARD, or a biologic (77%/74%) https://t.co/nTJO04sn65 https://t.co/gLjKzj2c74

Links:

Dr. John Cush RheumNow ( View Tweet)
RCT of 122 active plaque Psoriasis pts (38F, 55M) with low vitamin D (~15). Rx w/ either PBO or Vit D (100K IU, followed by 20K IU/wk x 4 mos). Vitamin D supplementation had no effect on psoriasis severity (but pts had mild PSO). https://t.co/JXtEBaop3c https://t.co/ScGtBUIrm0

Links:

Dr. John Cush RheumNow ( View Tweet)
What happens to PsA in pregnancy? 1/3 with mod-severe disease Little evidence of change of disease activity in pregnancy Disease may increase post-partum Christina Chambers @mothertobaby #RNL2023 @RheumNow https://t.co/0QAxhHb45u https://t.co/zb0YSaqiOf

Links:

Dr. John Cush RheumNow ( View Tweet)
Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis Analysis of patient data from five Nordic registries shows that the uptake of newer b/tsDMARDs in PsA was mainly in biologic-experienced patients. https://t.co/SP9ZKGvM0J https://t.co/1tfSiWHYfl

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Modern Management of PsA Faculty Panel Q&A , https://t.co/WIESJSL8WF https://t.co/0k7FyYkFtc

Links:

Dr. John Cush RheumNow ( View Tweet)
Pregnancy in PsA RheumNow Live 2023: Christina Chambers, PhD, MPH, University of California, San Diego School of Medicine https://t.co/QR0Mb7F1x3 https://t.co/rj6HtoUTpE

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors in Psoriasis and PsA RheumNow Live 2023: Eric Ruderman, MD, Northwestern University, Feinberg School of Medicine https://t.co/eVwQ6ITzD7 https://t.co/GZxVx77aV1

Links:

Dr. John Cush RheumNow ( View Tweet)
Pregnancy in PsA RheumNow Live 2023: Christina Chambers, PhD, MPH, University of California, San Diego School of Medicine https://t.co/ImgAwCvawE https://t.co/9GCZ1tBmkV

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors in Psoriasis and PsA RheumNow Live 2023: Eric Ruderman, MD, Northwestern University, Feinberg School of Medicine https://t.co/OV4rRR6eCh https://t.co/uY9MnwGveV

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/0mC7PxF0DU https://t.co/klbnwjcPbM

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×